Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00502385

Enrollment

Registered

2007-07-17

Start date

2004-04-30

Completion date

Unknown

Last updated

2011-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukaemia, Myelocytic, Acute

Keywords

Phase I, AML, de novo or secondary AML, AZD2171

Brief summary

The study will be conducted across multiple European centres to assess the safety and tolerability of multiple doses of AZD2171 in patients with AML.

Interventions

DRUGAZD2171

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Provision of written informed consent * Male/female, 18 yrs or over * WHO performance status 0-2 * Disease not responding to or relapsing after chemotherapy or elderly patients not suited to chemotherapy

Exclusion criteria

* Acute myeloid leukaemia arising from previous chronic myeloid leukaemia or acute myeloid leukaemia of type FAB M3 * Previous treatment against new blood vessel formation (anti-angiogenic) * Chest X-ray showing leukaemia in the lungs

Design outcomes

Primary

Measure	Time frame
The primary objective is to determine the safety and tolerability of multiple oral doses of AZD2171 in AML patients by assessment of AEs, BP&pulse, heart rate respiration rate, EKG, clinical chemistry	—

Secondary

Measure	Time frame
Efficacy, PK	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026